Fig. 4
From: Characteristics of clinical trials related to hip fractures and factors associated with completion
Cumulative completion curves. a Enrollment (1 indicates ≤ 50; 2 indicates > 50 and ≤ 100; 3 indicates > 100 and ≤ 200; 4 indicates > 200 and ≤ 400; and 5 indicates > 400; P < 0.01, log-rank test); b Funded by the National Institutes of Health (P < 0.01, log-rank test), c Interventions involving drugs/biologics (P < 0.01, log-rank test); d location in the United States (P = 0.04, log-rank test); e location in Europe (P = 0.03, log-rank test); f location in Canada (P = 0.95, log-rank test)